MidAmerica Healthcare Venture Forum: Speakers

Speakers

Matt Alves
Avinash N. Amin, M.D.
Bonnie Baskin, Ph.D.
Michael C. Burgess, M.D.
David M. Darst
Kevin Driscoll
Carol Frankenstein
Jan Garfinkle
Kevin Grumbach, M.D.

Robbie Huffines
Peter Kleinhenz
John McIlwraith
Joe Morgan, C.F.A.
John Neis
Gary M. Noonan
Robert J. Palay
Bonnie R. Plunkett
Maribeth S. Rahe
Sanuj Ravindran, M.D.

Mark T. Regal, C.F.A.
Fred M. Schwarzer
Baiju R. Shah
Anupendra Sharma
Dan Sheehan
John Sheils
Kate Sidebottom Simpson
Mina Patel Sooch, M.B.A.
Spencer L. Timm
Kathy Tune

Matt Alves: Vice President, Strategic Development
Stryker Instruments; Mr. Alves graduated from the Massachusetts Institute of Technology in 1980 with a degree in Mechanical Engineering. From 1980 to 1982, Mr. Alves worked for Corning Glass Works as a Manufacturing Engineer and a Process Engineer in the Medical Division. After obtaining a degree in General Management from Harvard Business School in 1984, he joined Stryker as assistant to the President. He has held the following positions at Stryker: Director of Manufacturing Engineering, R&D Director, Marketing Manager, Director of Marketing, Vice President of Marketing, and then, Vice President of Strategic Development, his current position. Throughout his career at Stryker, he has seen the company grow from $87 million to $6 billion. Mr. Alves currently coordinates acquisitions and business development activities for the four business units under the Instruments Division.

Avinash N. Amin, M.D.: Senior Vice President
Summit Strategies Group; Avi is the head of private equity at Summit Strategies Group, an institutional consulting firm based in St. Louis, MO with over 70 institutional clients and over $100B in assets advised. Summit clients invest more than $1B in private equity and venture capital on an annual basis. Prior to joining Summit, Avi worked as the head of Clinical Development at Novactyl, Inc., an R&D pharmaceutical company focused on dermatology products. Avi also co-founded TSVI, a global BPO company. Avi holds BA and MD degrees from Washington University in St. Louis and is board certified in Internal Medicine.

Bonnie Baskin, Ph.D.: Founder and past CEO
AppTec; Bonnie Baskin, Ph.D., is the founder and past CEO of AppTec, an international provider of regulatory-compliant testing and cGMP manufacturing services for biopharmaceuticals and medical devices. She founded her first company – ViroMed Laboratories – in the early 1980s and built it from a small independent virology laboratory into a nationally recognized leader in clinical and industrial biosafety testing. After steering the acquisition of the clinical part of that business by Laboratory Corporation of America in 2001, she reorganized the remaining biotech/medical device components as AppTec, secured venture capital to further grow the company, successfully expanded AppTec’s services into biopharm manufacturing and in 2008 sold AppTec to WuXi Pharmatech. Baskin serves on a number of private and non-profit boards and is a past president of MNBIO.

Michael C. Burgess, M.D.: US Congressman
State of Texas; U.S. Congressman Michael C. Burgess, M.D. worked as a doctor in Denton County for over 21 years. A respected physician of Obstetrics and Gynecology, Dr. Burgess delivered more than 3000 babies in North Texas before heading to Congress in 2003.

Rep. Burgess has four degrees: two from the now University of North Texas, an M.D. from the University of Texas Medical School in Houston and another Masters degree in Medical Management from the University of Texas at Dallas in 2000.

Since his election in 2002, Congressman Michael Burgess has made amazing strides in pushing legislative priorities including modernizing America’s health care system, building a strong defense, protecting our Homeland, cutting wasteful government spending, reforming the tax code, and making America energy self-sufficient.

Elected in 2002 and re-elected in 2004 and 2006, Congressman Michael Burgess serves as a member of the House Energy and Commerce, Transportation and Infrastructure, Government Reform and Science Committees. Congressman Burgess sits on four subcommittees: Health, Energy, Oversight and Investigations, and Commerce, Trade and Consumer Protection.

Committee assignments, writing legislation, reviewing intelligence reports, and hosting meetings with constituents are but a few of the activities in the everyday life of Congressman Michael C. Burgess.

David M. Darst: Associate
OrbiMed Advisors; David M. Darst, joined OrbiMed Advisors, LLC in 2007 to identify investments in biotechnology and medical device companies. Mr. Darst is a co-founder of two biotechnology companies with treatments in development for Age-Related Macular Degeneration and for Tuberculosis. He also co-founded an internet health company, and worked as a summer associate with McKinsey & Company, Pfizer, and Millennium Pharmaceuticals. Mr. Darst earned an A.B. degree cum laude from Harvard College and an M.B.A. from Harvard Business School. Mr. Darst serves on the board of Potentia Pharmaceuticals, Inc.

Kevin Driscoll: Director, Global New Business & Technology Development
Procter & Gamble Health Care; Dr. Kevin Driscoll is the Director of Global New Business & Technology Development for Procter & Gamble Pharmaceuticals. He joined P&G in 1986 and has held numerous leadership positions across P&G businesses in Health and Beauty Care, most recently, serving as Director, Pharmaceuticals Discovery Research. In 2006, Dr. Driscoll was appointed to his current role in which he leads P&G Pharmaceuticals’ global efforts to find, evaluate and in-license new pharmaceutical compounds, devices and diagnostics. He also is responsible for the pharmaceutical development pipeline from preclinical through proof of concept. Outside of P&G, Dr. Driscoll has served in numerous advisory roles for the U.S. Environmental Protection Agency; Food & Drug Administration; World Health Organization; and, the National Research Council’s (NRC) Committee on Toxicology.

Carol Frankenstein: President
BioStart; Carol J. Frankenstein is the President of BIOSTART, Cincinnati's bio/medical business start-up center and regional affiliate of BioOhio, Ohio’s life science industry association. With over 20 years experience in health care management, she has had a role in guiding 100 life science companies and over 300 entrepreneurs. Under her leadership, start-up clients have generated over $170 MM in grant, research contract and equity investments and created 180 jobs. She co-founded SoundingBoard^SM a regional business plan review program and Cincinnati Creates Companies, a regional business plan writing program for technology businesses. She has an MBA from the University of Chicago and a BA from Ohio State University. She serves on the Federal Reserve Bank Regional Business Advisory Board, and is the past chair of the Ohio’s Thomas Edison Incubator Director’s Council.

Jan Garfinkle: Managing Director
Arboretum Ventures; Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering to select and nurture outstanding companies. Jan currently serves on the board of directors for HandyLab, VasoNova, Mirabilis Medica, and NXThera and as an observer for Uptake Medical, BAROnova and Esperion Therapeutics. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions and was Founder and President of Strategic Marketing Consultants. Earlier in her career, Jan was part of the senior management team for two successful medical device start-up companies, advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired and became part of Guidant Corporation. Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Kevin Grumbach, M.D.: Professor and Chair of the Department of Family and Community Medicine
University of California, San Francisco; Chief of Family and Community Medicine
San Francisco General Hospital; Kevin Grumbach, MD is Professor and Chair of the Department of Family and Community Medicine at the University of California, San Francisco and Chief of Family and Community Medicine at San Francisco General Hospital. He is the Director of the UCSF Center for California Health Workforce Studies, Co-Director of the UCSF Center for Excellence in Primary Care, and Co-Director of the Community Engagement Program for the UCSF Clinical Translational Science Institute. His research has been published in major medical journals such as The New England Journal of Medicine and JAMA and is cited widely. He co-authored what has become the best-selling textbook on health policy, Understanding Health Policy - A Clinical Approach, and recently, Improving Primary Care – Strategies and Tools for a Better Practice, both published by McGraw Hill-Lange. He received a Generalist Physician Faculty Scholar award from the Robert Wood Johnson Foundation, the Health Resources and Services Administration Award for Health Workforce Research on Diversity, and in 1997 was elected a member of the Institute of Medicine, National Academy of Sciences.

Robbie Huffines: Co-head of the Global Healthcare Investment Banking Group
J.P. Morgan Chase; Mr. Huffines joined J.P. Morgan in 1992 and is currently co-head of the global healthcare investment banking group. Mr. Huffines is primarily focused on pharmaceutical, medical device and biotechnology clients. Mr. Huffines has advised numerous healthcare companies on strategic transactions, including: Amgen’s sale of Amgen K.K. to Takeda, Sirtris Pharmaceutical’s sale to Glaxo SmithKline, Guidant’s sale to Boston Scientific and Abbott, Merck's acquisitions of Banyu Pharmaceuticals; Bristol-Myers Squibb's divestitures of Medical Imaging, Zimmer and Mead Johnson’s adult nutrition business and acquisition of DuPont Pharmaceuticals; L’Oreal on the Sanofi-Aventis merger; Biorexis sale to Pfizer, Sofamor Danek's sale to Medtronic; Oratec’s sale to Smith & Nephew; Johnson & Johnson's acquisitions of Mitek, Cordis, and Neutrogena; Fujisawa's sale of its multisource pharmaceutical business.

Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financings and advisory assignments for emerging growth companies. Mr. Huffines has an M.B.A. from the University of Virginia, where he received the faculty award for academic excellence. He has a B.A. from the University of North Carolina, where he majored in English and Economics. Mr. Huffines is married and has four children. His volunteer work includes The Brookings/Gates Global Health Innovative Financing Advisory Group, the Student Sponsor Partnership, and serving as a board member of the Spence School.

Peter Kleinhenz: Managing Director
CID Capital; Peter Kleinhenz is a Managing Director of CID Capital. He has been actively involved in technology-based businesses as an entrepreneur, consultant, and investor for over 20 years and leads CID's investments in life sciences. Prior to joining CID, Peter served as VP of Commercialization for Battelle Memorial Institute and as an independent consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups. Peter was CEO of Progenics, which he sold to Fitch, Inc., an international product design and development firm and served in a variety of senior executive positions at Neoprobe Corporation, a biotech device company focused on cancer diagnostics and therapeutics. Peter received an MBA from The Weatherhead School of Management at Case Western Reserve University, a BA degree in history from Loyola University of Chicago, and is a Certified Public Accountant, Ohio inactive license.

John McIlwraith: Managing Director
Blue Chip Venture Company; John McIlwraith leads Blue Chip’s Healthcare industry practice and is responsible for the firm’s investments in Endocyte, Xanodyne Pharmaceuticals, Renal Solutions, and HealthScribe, reflecting his focus on investments in drug, device, and technology-enabled healthcare services companies.

Before joining Blue Chip in 1997, John was the senior vice president of strategic planning of Indianapolis-based Quantum Health Resources, a publicly-traded healthcare services company that provided drugs and related therapies to patients with rare chronic diseases. At Quantum, John led business development efforts, including managed care initiatives and new drug launches for Biogen and Glaxo. Prior to Quantum, John was a partner with the Jones Day law firm where he co-founded the firm’s Private Ventures practice group. While at Jones Day, John represented venture capital firms and a number of early-stage healthcare companies. Education: JD, Case Western Reserve University; BA, Hillsdale College.

Joe Morgan, C.F.A.: Chief Investment Officer and Head of Portfolio Management
SVB Asset Management; Joe Morgan is the chief investment officer and head of portfolio management for SVB Asset Management. He has more than 15 years of experience managing fixed income portfolios for the purpose of total return, current income, and liability diffusion. In his current role, Morgan leads a team of portfolio managers and traders that sets and executes investment strategy for all of SVB Asset Management’s client investments.

Morgan is widely sought out for his commentary on issues affecting the fixed income market and is most recognized for his leadership in exiting and speaking out about the substantial risks associated with auction rate securities since 2004. The Wall Street Journal called Morgan, “The Auction Rate Cassandra” once the market started to fail in 2008.

Prior to joining SVB, Morgan was a senior portfolio manager with City National Asset Management in Beverly Hills, and was responsible for the bank's taxable fixed income total return oriented clients. He also spent seven years with Seneca Capital Management in San Francisco. At Seneca, he was responsible for managing institutional fixed income assets totaling over $5 billion with various return objectives and benchmarks.

Morgan received both his bachelor's and master's degrees in finance from Texas A&M University, and is a Chartered Financial Analyst. He resides in Danville with his wife.

John Neis: Managing Director
Venture Investors, LLC; John Neis is a Managing Director of Venture Investors LLC, an early stage venture capital firm with offices in Madison, Wisconsin and Ann Arbor, Michigan. John heads the firm's Health Care practice. He currently serves on the Board of Directors of three portfolio companies: Virent Energy Systems, Cellectar, and Deltanoid Pharmaceuticals. He was appointed by the Governor to the Board of the Wisconsin Technology Council, the science and technology advisor to Wisconsin’s Governor and Legislature. He serves on the Advisory Board of the Weinert Applied Ventures Program and on the Dean’s Advisory Board in the School of Business at the University of Wisconsin – Madison. He graduated Magna Cum Laude with a B.S. in finance from the University of Utah, and received a M.S. in Marketing and Finance from the University of Wisconsin – Madison. He is a Chartered Financial Analyst.

Gary M. Noonan: Senior Director, Corporate Business Development
Eli Lilly and Company; Gary Noonan has been a Director in Corporate Business Development for Eli Lilly since 1996 and has been a management team member in that group since 1990. During this period, his responsibility has varied from outpartnering Lilly assets to opportunities arising from Europe to his current focus of the discovery and enabling technologies such as genomics, proteomics, antisense, target platforms, diagnostics/biomarkers as well as key deals in China and India.

Mr. Noonan joined Lilly in May 1978 and has had a variety of positions including pricing studies associate, market research associate, district sales manager, and new product planning manager for diabetes. He has also lived in London where he was the European product manager for neuroscience, focusing upon the introduction of Prozac in major Europe.

He received a BA in biological sciences from Indiana University in 1975 and an MBA from Indiana University in 1978.
He serves on the Board of Directors as an observer for CoLucid Pharmaceuticals, Inc., and he is also a Board member of Muroplex Therapeutics, Inc..

Robert J. Palay: Chairman of the Board & CEO
NimbleGen Systems; Robert J. Palay, Chairman of the Board & CEO, has been a founder or early stage investor in genomics and stem cell based companies for over a decade. He was a founder and chairman of NimbleGen Systems, Inc. a molecular biology tools company. He also served as its CEO at various stages prior to its sale to Roche for $272 million in August 2007. Mr. Palay is also a founder and principal of Tactics II Ventures, LP and Tactics II Stem Cell Ventures, LP. Since 1991, Bob has also served as the Chairman of Tactics II Group, a Midwestern merchant banking and investment partnership with significant investment activity in next generation biotechnology companies. From 1986 until 1991, Bob was Vice President, Acquisitions for Sam Zell’s Equity Group, where Bob focused on acquiring distressed assets. Prior to joining Mr. Zell’s organization, Bob practiced law at Rudnick & Wolfe in Chicago, Illinois. Bob earned a J.D. from Northwestern University and an M.B.A. from the J.L. Kellogg Graduate School of Management (Northwestern University). He graduated magna cum laude from Harvard College in 1978 with an A.B.

Bonnie R. Plunkett: Managing Director
Alternative Investment Source LLC; Founded Alternative Investment Source LLC, a placement agent, in 1999, the firm has had tremendous success in representing high calibre emerging managers and in assisting more experienced fund managers in LP diversification and round-out raises. Bonnie has extensive financial and investment expertise with 20 years experience on both sides of the funding aisle. Previously Director of Marketing/Client Services for Provident Capital Management and also Meridian Investment Company. Recognized for her expertise in management of endowment, foundation and public funds, her articles have been published nationally. She has a keen sense of civic/community commitment and has received numerous awards for both her professional achievements and community involvement. Member of The Forum of Executive Women, board member Opera Company of Philadelphia, past Board member and Assistant Treasurer, Cradle of Liberty Boy Scout Council. Awards include: Boy Scouts of America Silver Beaver Award, the highest award bestowed at the Council level; Philadelphia’s Summit Award for outstanding professional and community accomplishments, “Distinguished Alumnus Award” from her college alma mater; one of 500 women statewide appointed to the “Pennsylvania Honor Role of Women” by the Pennsylvania Governor’s Executive Office, Pennsylvania Commission for Women; Pennsylvania’s “Best 50 Women in Business” by the Governor’s office, Pennsylvania Department of Community & Economic Development and Pennsylvania’s Business Journals. Graduate Albright College; attended Cornell University’s School of Management. Registered Representative with Griffin Financial Group LLC. Member FINRA, Member SIPC.

Maribeth S. Rahe: President & CEO, Fort Washington Investment Advisors
Senior Vice President, Western & Southern Financial Group®
Chairman, Capital Analysts, Inc.; Rahe is one of five women in executive management at Western & Southern. Under her leadership, Fort Washington is the largest investment advisor in Ohio. Fort Washington provides professional and comprehensive asset management services for institutions, insurance companies, foundations, endowments, associations and high net-worth individuals. Prior to joining Western & Southern, Rahe was President and a board member of the US Trust Company, New York; Vice Chair of the board of The Harris Bank, Chicago; and held various positions at JPMorgan in London and New York.

A Chicago native, Rahe is a graduate of Bowling Green State University and earned her MBA in International Management from Thunderbird School of Global Management in Glendale, Arizona. A well-known expert in financial services, Ms. Rahe and her husband, Martin, currently reside in Cincinnati, Ohio along with their three dogs.

Sanuj Ravindran, M.D.: Principal
Radius Ventures; Sanuj K. Ravindran, M.D. is a Principal of Radius Ventures. Prior to joining Radius in February 2007, Sanuj was a Director at Burrill & Company, a San Francisco based life science venture capital firm. While with Burrill, he served as a board observer to diaDexus and Proventys, and played an active role in several other investments, including Endocyte, Neosil, Cardiokine and Arete Therapeutics. Previously, Sanuj worked in the Healthcare Investment Banking Group at Merrill Lynch. He is Board Certified in Internal Medicine and served as a National Cancer Institute Research Fellow at Memorial Sloan Kettering Cancer Center. He is also a member of the Kauffman Fellows Program. Sanuj received a B.A. with Honors from Northwestern University, an M.D. from Jefferson Medical College, and an M.B.A from The Kellogg School of Management, where he was a Rothschild Scholar.

Mark T. Regal, C.F.A.: Partner, Customized Fund Investment Group
Credit Suisse; Mark is a Partner in the Customized Fund Investment Group. Previously, Mark was a Senior Associate in Prudential’s private equity group and had responsibility for reviewing Prudential’s private equity partnership investments. Prior to joining Prudential, Mark was employed by BankAmerica Capital Corporation, where he was charged with the day-to-day responsibilities of its venture capital fund portfolio. Prior to that, Mark was an Analyst for Alternative Investments at the Minnesota State Board of Investment. Prior to that, Mark was employed at the Minneapolis law firm of Popham Haik Schnobrich & Kaufman. He is a Chartered Financial Analyst, a member of the CFA Institute and a member of the New York Society of Security Analysts, where he serves on the Alternative Investments Committee.

Fred M. Schwarzer: Managing Partner
Charter Life Sciences; Fred M. Schwarzer is a Managing Partner at Charter Life Sciences, an early stage life sciences venture capital fund. Fred has extensive operational and fundraising experience, including the development of corporate partnerships and the structuring of venture capital investments and acquisitions. Prior to founding CLS, Fred was the CEO and then chairman of Heska (HSKA). During his tenure at Heska, Fred completed corporate partnerships with Bayer and Novartis, seven acquisitions and Heska’s IPO and follow-on public offering. Fred has also been the president and CEO of Mingly Capital Corporation and executive director of the Mingly Corporation Limited. Prior to that, he was a senior vice president of C.M. Capital, a diversified asset management company. Fred began his professional career as an attorney representing technology companies and venture capitalists. In 1985, he was made a Partner with Pillsbury, Madison & Sutro (now Pillsbury, Winthrop) and in 1988 he founded the firm of General Counsel Associates (now GCA Law Partners). Mr. Schwarzer received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. from the University of Michigan.

Baiju R. Shah: President
BioEnterprise Corporation; Baiju R. Shah is President and CEO and a Founder of BioEnterprise, a partnership of Case Western, Cleveland Clinic, Summa Health, and University Hospitals. BioEnterprise is a business acceleration initiative to support the growth of bioscience companies. Since 2002, it has helped more than 80 Cleveland companies that have collectively attracted more than $750 million in new funding. Prior to BioEnterprise, Shah was with McKinsey & Company, where he played a leading role in the Growth and Business Building practice. In the community, Shah serves on the Governor’s Biomedical, Strategic Development, and Workforce Policy Advisory Boards, as well as the Boards of The Saint Luke’s Foundation, Great Lakes Science Center, Yale Alumni Association, NorTech, and Summer on the Cuyahoga. Shah has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland’s most powerful and influential leaders by several publications. Shah received a J.D. from Harvard and his B.A. from Yale.

Anupendra Sharma: Investment Partner
Siemens Venture Capital; Anupendra Sharma is Investment Partner in the Medical Solutions Fund at Siemens Venture Capital in Boston. Anupendra is most actively focused on investing in US, China and Israel. His areas of focus include medtech devices, imaging equipment and applications, in-vitro and point of care diagnostics, biomarkers, navigation systems, healthcare IT and software, and oncology therapy. Anupendra is involved in SVC investments in Sequenom and U-Systems. Previously, he was Director of Mergers & Acquisitions at Siemens Corporation, responsible for Medical transactions in the USA. Anupendra has completed over $3 billion of acquisitions and divestitures, especially in the medical imaging, healthcare IT, software and healthcare services sectors. Prior to joining Siemens Corporation, Anupendra worked in Investment Banking at JPMorgan and Salomon Smith Barney in New York, strategy consulting for McKinsey in London, and Product Development Finance for Ford Motor in the UK, where he was a member of the core team that launched Ford in China and India. Anupendra is a Charter Member of TiE Boston, and Founder & Chairman of Mobile Medics, a social venture attempting to solve the last-mile problem for rural healthcare. Mobile Medics was named the Most Outstanding Social Venture of 2006 at the Global Social Venture Competition, and has won several international awards. Anupendra holds an MBA from Cornell University, MS in Accounting & Finance from Manchester Business School, Masters in Economics and Bachelors in Instrumentation Engineering from BITS Pilani, India.

Dan Sheehan: Vice President
Covidien Ventures; Dan Sheehan manages the activities of Covidien Ventures. Dan is passionate about working with the managers of entrepreneurial companies and understands the complexity of commercializing new medical technologies. His background includes both venture capital investing and operating company management roles in the healthcare sector. Most recently, Dan was a General Partner with Affinity Capital Management, a healthcare oriented venture capital firm in Minneapolis. He has also managed the business development and strategic marketing efforts for Steris Corporation, a provider of infection prevention and surgical support products for the healthcare and life sciences sectors.

John Sheils: Senior Vice President
The Lewin Group; John Sheils is Senior Vice President of The Lewin Group, a premier national health care and human services consulting firm with more than 35 years’ experience finding answers and solving problems for leading organizations in the public, nonprofit, and private sectors. Mr. Sheils is a nationally known authority on the cost and coverage impacts of proposals to expand health insurance coverage and reform the health care system. He has been providing health care policy consulting services with The Lewin Group for over 20 years.

John works with a variety of clients including state governments and legislatures, the federal government, private associations, foundations and health plans. He has testified before various Congressional committees and commissions on health reform and is often quoted in the media. He often works directly with members of Congress in designing health reform proposals.

John received a Masters in Public Policy from the Heinz School at Carnegie Mellon University and a BA from the State University of New York at Brockport.

Kate Sidebottom Simpson: Vice President
Parish Capital; Ms. Simpson joined Parish Capital in April 2006. As a Vice President, Ms. Simpson is responsible for reviewing investment opportunities, conducting due diligence on potential investments and monitoring those investments and their underlying companies. Prior to joining Parish Capital, Ms. Simpson worked as an Investment Associate with the UNC Management Company, an investment management firm which provides services to The University of North Carolina. In this role, she helped to manage several alternative investment portfolios, including private equity, venture capital, real estate, energy/natural resources and enhanced fixed income. She worked on all aspects of endowment management including asset allocation, portfolio construction and risk management, manager selection, manager performance evaluation and reporting to the Investment Fund Board. Ms. Simspon received her BA in History (Chemistry minor) with Distinction and with Honors, Phi Beta Kappa, from the University of North Carolina at Chapel Hill, where she was a member of the NCAA Championship women’s Field Hockey team.

Mina Patel Sooch, M.B.A.: Founder and Managing Director
Apjohn Ventures; Mina Sooch brings with her over fifteen years of pharmaceutical and healthcare experiences as an entrepreneur, strategy & finance advisor, and venture capitalist. Since 2000, she has helped co-found Apjohn Ventures, Apjohn Group, and several local start-ups. Mina has served on 8 portfolio company boards as a venture investor and serves on the boards of the Midwest Healthcare Investment Network and Michigan Venture Capital Association. Prior to 2000, Mina spent eight years as a global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with her client base consisting of mid-cap and large-cap healthcare companies and multi-billion dollar private equity companies. With a focus on M&A, she has worked on over 30 deals including $7B Pharmacia & Upjohn merger in 1995. Mina was also a co-founder of Monitor's Corporate Finance practice in 1998. Mina received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.

Spencer L. Timm: Investor Relations Partner
Morgenthaler Ventures; Spencer, based in West Chesterfield, MA, joined Morgenthaler as a consultant in 1997 and became an Investor Relations Partner in 1998. He focuses principally on fundraising and investor relations. Prior to joining the firm he spent eight years in the securities industry where he managed the sales training school at E.F. Hutton, and was VP Marketing for the Boston Stock Exchange. Subsequently, he was in the investment management industry, as the head of institutional marketing for State Street Bank (now SSGA), and a founding principal of Franklin Portfolio Associates.
He has been and continues to be, a trustee and advisor to numerous endowments including The Boston Foundation, The Community Foundation of Western Massachusetts, and Virginia State University. Spencer graduated from The College of William and Mary in 1966.

Kathleen A Tune: Associate
Thomas McNerney Partners; Kathy joined Thomas, McNerney & Partners from Piper Jaffray, where she was a health care analyst focused on medical technology companies. While at Piper, Kathy covered over 20 companies in the medical device, medical supply and diagnostic areas. Her background also includes experience in new product development at Solvay, S.A. (in a division that is now part of Wyeth). Projects at Solvay included the development of vaccines for the prevention of viral infections. Kathy also was a Senior Scientist in molecular biology at the University of Minnesota, where she worked on the development of molecular biology based assays for the detection of infectious agents. Kathy is currently a board member of Softscope Medical Technologies, Inc. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.